Drug intelligence / Profile preview

MAG-024

Development stage: Preclinical
Lead developer: MacroGenics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

MAG-024 is a preclinical-stage bispecific monoclonal antibody being developed by Miragene. The molecule is engineered for an extended half-life, a modification typically designed to enhance its pharmacokinetic profile and potentially allow for less frequent dosing. While the specific molecular targets and therapeutic indications have not yet been publicly disclosed, the drug is designed to simultaneously engage two distinct biological pathways. As of 2024, MAG-024 remains in the preclinical phase of development as part of Miragene's pipeline of multi-specific biologics.

Beyond the preview

Go deeper on MAG-024.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAG-024.

Explore the full profile